For the quarter ended | Commission File Number |
March 31, 2016 | 0-16093 |
New York (State or other jurisdiction of incorporation or organization) | 16-0977505 (I.R.S. Employer Identification No.) |
525 French Road, Utica, New York (Address of principal executive offices) | 13502 (Zip Code) |
PART I FINANCIAL INFORMATION | ||
Item Number | Page | |
PART II OTHER INFORMATION | ||
Three Months Ended | |||||||
March 31, | |||||||
2016 | 2015 | ||||||
Net sales | $ | 181,201 | $ | 177,940 | |||
Cost of sales | 83,461 | 85,658 | |||||
Gross profit | 97,740 | 92,282 | |||||
Selling and administrative expense | 85,943 | 74,786 | |||||
Research and development expense | 8,258 | 6,542 | |||||
Operating expenses | 94,201 | 81,328 | |||||
Income from operations | 3,539 | 10,954 | |||||
Other expense | 2,942 | — | |||||
Interest expense | 3,830 | 1,460 | |||||
Income (loss) before income taxes | (3,233 | ) | 9,494 | ||||
Provision (benefit) for income taxes | (968 | ) | 3,182 | ||||
Net income (loss) | $ | (2,265 | ) | $ | 6,312 | ||
Comprehensive income (loss) | $ | 787 | $ | (3,715 | ) | ||
Per share data: | |||||||
Net income | |||||||
Basic | $ | (0.08 | ) | $ | 0.23 | ||
Diluted | (0.08 | ) | 0.23 | ||||
Dividends per share of common stock | $ | 0.20 | $ | 0.20 | |||
Weighted average common shares | |||||||
Basic | 27,721 | 27,573 | |||||
Diluted | 27,721 | 27,820 |
March 31, 2016 | December 31, 2015 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 19,894 | $ | 72,504 | |||
Accounts receivable, net | 134,412 | 133,863 | |||||
Inventories | 185,108 | 166,894 | |||||
Prepaid expenses and other current assets | 28,520 | 20,076 | |||||
Total current assets | 367,934 | 393,337 | |||||
Property, plant and equipment, net | 126,827 | 125,452 | |||||
Goodwill | 398,387 | 260,651 | |||||
Other intangible assets, net | 434,196 | 308,171 | |||||
Other assets | 15,439 | 14,089 | |||||
Total assets | $ | 1,342,783 | $ | 1,101,700 | |||
LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Current portion of long-term debt | $ | 10,089 | $ | 1,339 | |||
Accounts payable | 29,030 | 34,720 | |||||
Accrued compensation and benefits | 27,580 | 31,823 | |||||
Other current liabilities | 36,459 | 51,836 | |||||
Total current liabilities | 103,158 | 119,718 | |||||
Long-term debt | 511,598 | 269,471 | |||||
Deferred income taxes | 119,433 | 103,379 | |||||
Other long-term liabilities | 26,305 | 24,059 | |||||
Total liabilities | 760,494 | 516,627 | |||||
Commitments and contingencies | |||||||
Shareholders' equity: | |||||||
Preferred stock, par value $ .01 per share; | |||||||
authorized 500,000 shares; none outstanding | — | — | |||||
Common stock, par value $ .01 per share; | |||||||
100,000,000 shares authorized; 31,299,194 shares | |||||||
issued in 2016 and 2015, respectively | 313 | 313 | |||||
Paid-in capital | 325,886 | 324,915 | |||||
Retained earnings | 406,695 | 414,506 | |||||
Accumulated other comprehensive loss | (50,842 | ) | (53,894 | ) | |||
Less: 3,556,032 and 3,590,409 shares of common stock | |||||||
in treasury, at cost in 2016 and 2015, respectively | (99,763 | ) | (100,767 | ) | |||
Total shareholders’ equity | 582,289 | 585,073 | |||||
Total liabilities and shareholders’ equity | $ | 1,342,783 | $ | 1,101,700 |
Three Months Ended | |||||||
March 31, | |||||||
2016 | 2015 | ||||||
Cash flows from operating activities: | |||||||
Net income (loss) | $ | (2,265 | ) | $ | 6,312 | ||
Adjustments to reconcile net income | |||||||
to net cash provided by operating activities: | |||||||
Depreciation | 4,986 | 4,633 | |||||
Amortization | 8,272 | 5,537 | |||||
Stock-based compensation | 2,489 | 1,856 | |||||
Deferred income taxes | (2,942 | ) | 1,253 | ||||
Loss on early extinguishment of debt | 254 | — | |||||
Increase (decrease) in cash flows | |||||||
from changes in assets and liabilities, net of acquired assets: | |||||||
Accounts receivable | 11,428 | (3,805 | ) | ||||
Inventories | (10,720 | ) | (1,155 | ) | |||
Accounts payable | (11,109 | ) | 3,733 | ||||
Accrued compensation and benefits | (7,519 | ) | (4,485 | ) | |||
Other assets | (7,662 | ) | 2,917 | ||||
Other liabilities | (2,492 | ) | (1,987 | ) | |||
(15,015 | ) | 8,497 | |||||
Net cash provided by (used in) operating activities | (17,280 | ) | 14,809 | ||||
Cash flows from investing activities: | |||||||
Purchases of property, plant and equipment | (2,789 | ) | (4,061 | ) | |||
Payments related to business acquisitions, net of cash acquired | (256,424 | ) | (853 | ) | |||
Net cash used in investing activities | (259,213 | ) | (4,914 | ) | |||
Cash flows from financing activities: | |||||||
Payments on senior credit agreement | (2,188 | ) | — | ||||
Proceeds from senior credit agreement | 253,005 | 17,000 | |||||
Payments related to distribution agreement | (16,667 | ) | (16,667 | ) | |||
Payments related to debt issuance costs | (5,556 | ) | — | ||||
Dividends paid on common stock | (5,542 | ) | (5,510 | ) | |||
Other, net | 110 | 543 | |||||
Net cash provided by (used in) financing activities | 223,162 | (4,634 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents | 721 | (5,864 | ) | ||||
Net decrease in cash and cash equivalents | (52,610 | ) | (603 | ) | |||
Cash and cash equivalents at beginning of period | 72,504 | 66,332 | |||||
Cash and cash equivalents at end of period | $ | 19,894 | $ | 65,729 | |||
Non-cash financing activities: | |||||||
Dividends payable | $ | 5,546 | $ | 5,516 |
Three Months Ended March 31, | |||||||
2016 | 2015 | ||||||
Net income (loss) | $ | (2,265 | ) | $ | 6,312 | ||
Other comprehensive income (loss): | |||||||
Pension liability, net of income tax (income tax expense of $257 and $300 for the three months ended March 31, 2016 and 2015, respectively) | 438 | 512 | |||||
Cash flow hedging gain (loss), net of income tax (income tax expense (benefit) of ($1,299) and $1,150 for the three months ended March 31, 2016 and 2015, respectively) | (2,217 | ) | 1,962 | ||||
Foreign currency translation adjustment | 4,831 | (12,501 | ) | ||||
Comprehensive income (loss) | $ | 787 | $ | (3,715 | ) | ||
Cash Flow Hedging Gain (Loss) | Pension Liability | Cumulative Translation Adjustments | Accumulated Other Comprehensive Income (Loss) | ||||||||||||
Balance, December 31, 2015 | $ | 1,201 | $ | (25,982 | ) | $ | (29,113 | ) | $ | (53,894 | ) | ||||
Other comprehensive income (loss) before reclassifications, net of tax | (1,891 | ) | — | 4,831 | 2,940 | ||||||||||
Amounts reclassified from accumulated other comprehensive income (loss) before taxa | (517 | ) | 695 | — | 178 | ||||||||||
Income tax provision (benefit) | 191 | (257 | ) | — | (66 | ) | |||||||||
Net current-period other comprehensive income (loss) | (2,217 | ) | 438 | 4,831 | 3,052 | ||||||||||
Balance, March 31, 2016 | $ | (1,016 | ) | $ | (25,544 | ) | $ | (24,282 | ) | $ | (50,842 | ) |
Cash Flow Hedging Gain (Loss) | Pension Liability | Cumulative Translation Adjustments | Accumulated Other Comprehensive Income (Loss) | ||||||||||||
Balance, December 31, 2014 | $ | 3,276 | $ | (30,760 | ) | $ | (12,338 | ) | $ | (39,822 | ) | ||||
Other comprehensive income (loss) before reclassifications, net of tax | 275 | — | (12,501 | ) | (12,226 | ) | |||||||||
Amounts reclassified from accumulated other comprehensive income before taxa | 2,676 | 812 | — | 3,488 | |||||||||||
Income tax provision (benefit) | (989 | ) | (300 | ) | — | (1,289 | ) | ||||||||
Net current-period other comprehensive income (loss) | 1,962 | 512 | (12,501 | ) | (10,027 | ) | |||||||||
Balance, March 31, 2015 | $ | 5,238 | $ | (30,248 | ) | $ | (24,839 | ) | $ | (49,849 | ) |
March 31, 2016 | Asset Balance Sheet Location | Fair Value | Liabilities Balance Sheet Location | Fair Value | Net Fair Value | |||||||||||
Derivatives designated as hedged instruments: | ||||||||||||||||
Foreign exchange contracts | Other current liabilities | $ | 930 | Other current liabilities | $ | (2,541 | ) | $ | (1,611 | ) | ||||||
Derivatives not designated as hedging instruments: | ||||||||||||||||
Foreign exchange contracts | Other current liabilities | 7 | Other current liabilities | (26 | ) | (19 | ) | |||||||||
Total derivatives | $ | 937 | $ | (2,567 | ) | $ | (1,630 | ) |
December 31, 2015 | Asset Balance Sheet Location | Fair Value | Liabilities Balance Sheet Location | Fair Value | Net Fair Value | |||||||||||
Derivatives designated as hedged instruments: | ||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other current assets | $ | 2,931 | Prepaid expenses and other current assets | $ | (1,026 | ) | $ | 1,905 | |||||||
Derivatives not designated as hedging instruments: | ||||||||||||||||
Foreign exchange contracts | Prepaid expenses and other current assets | 4 | Prepaid expenses and other current assets | (38 | ) | (34 | ) | |||||||||
Total derivatives | $ | 2,935 | $ | (1,064 | ) | $ | 1,871 |
March 31, 2016 | December 31, 2015 | ||||||
Raw materials | $ | 50,533 | $ | 47,681 | |||
Work-in-process | 15,211 | 13,922 | |||||
Finished goods | 119,364 | 105,291 | |||||
Total | $ | 185,108 | $ | 166,894 |
Three Months Ended March 31, | |||||||
2016 | 2015 | ||||||
Net income (loss) | $ | (2,265 | ) | $ | 6,312 | ||
Basic – weighted average shares outstanding | 27,721 | 27,573 | |||||
Effect of dilutive potential securities | — | 247 | |||||
Diluted – weighted average shares outstanding | 27,721 | 27,820 | |||||
Net income (loss) | |||||||
Basic (per share) | $ | (0.08 | ) | $ | 0.23 | ||
Diluted (per share) | (0.08 | ) | 0.23 |
Balance as of December 31, 2015 | $ | 260,651 | |
Goodwill resulting from business acquisitions | 136,358 | ||
Foreign currency translation | 1,378 | ||
Balance as of March 31, 2016 | $ | 398,387 |
March 31, 2016 | December 31, 2015 | ||||||||||||||
Gross Carrying Amount | Accumulated Amortization | Gross Carrying Amount | Accumulated Amortization | ||||||||||||
Amortized intangible assets: | |||||||||||||||
Customer and distributor relationships | $ | 213,338 | $ | (67,110 | ) | $ | 136,871 | $ | (64,423 | ) | |||||
Promotional, marketing and distribution rights | 149,376 | (25,500 | ) | 149,376 | (24,000 | ) | |||||||||
Patents and other intangible assets | 71,642 | (43,384 | ) | 66,688 | (42,885 | ) | |||||||||
Developed technology | 49,600 | (310 | ) | — | — | ||||||||||
Unamortized intangible assets: | |||||||||||||||
Trademarks and tradenames | 86,544 | — | 86,544 | — | |||||||||||
$ | 570,500 | $ | (136,304 | ) | $ | 439,479 | $ | (131,308 | ) |
Amortization included in expense | Amortization recorded as a reduction of revenue | Total | |||||||||
Remaining, 2016 | $ | 10,699 | $ | 4,500 | $ | 15,199 | |||||
2017 | 15,422 | 6,000 | 21,422 | ||||||||
2018 | 15,740 | 6,000 | 21,740 | ||||||||
2019 | 15,600 | 6,000 | 21,600 | ||||||||
2020 | 15,265 | 6,000 | 21,265 | ||||||||
2021 | 14,010 | 6,000 | 20,010 |
2016 | 2015 | ||||||
Balance as of January 1, | $ | 2,509 | $ | 2,286 | |||
Provision for warranties | 833 | 951 | |||||
Claims made | (841 | ) | (873 | ) | |||
Balance as of March 31, | $ | 2,501 | $ | 2,364 |
Three Months Ended March 31, | |||||||
2016 | 2015 | ||||||
Service cost | $ | 113 | $ | 67 | |||
Interest cost on projected benefit obligation | 719 | 888 | |||||
Expected return on plan assets | (1,297 | ) | (1,469 | ) | |||
Net amortization and deferral | 695 | 812 | |||||
Net periodic pension cost | $ | 230 | $ | 298 |
Three Months Ended March 31, | |||||||
2016 | 2015 | ||||||
Restructuring costs included in cost of sales | $ | 864 | $ | 2,329 | |||
Restructuring costs | $ | 2,791 | $ | 6,180 | |||
Business acquisition costs | 9,045 | — | |||||
Acquisition, restructuring and other expense included in selling and administrative expense | $ | 11,836 | $ | 6,180 | |||
Debt refinancing costs included in other expense | $ | 2,942 | $ | — |
2016 | 2015 | ||||||
Balance as of January 1, | $ | 7,175 | $ | 8,254 | |||
Expenses incurred | 3,655 | 8,509 | |||||
Payments made | (6,955 | ) | (7,885 | ) | |||
Balance at March 31, | $ | 3,875 | $ | 8,878 |
Three Months Ended March 31, | |||||||
2016 | 2015 | ||||||
Orthopedic surgery | $ | 93,441 | $ | 98,597 | |||
General surgery | 75,902 | 66,062 | |||||
Surgical visualization | 11,858 | 13,281 | |||||
Consolidated net sales | $ | 181,201 | $ | 177,940 |
December 31, 2015 | |||||||||||
As Filed | Reclass | As Adjusted | |||||||||
Current deferred income tax assets | $ | 14,150 | (14,150 | ) | — | ||||||
Long-term deferred income tax assets | 1,332 | 2,906 | 4,238 | ||||||||
Long-term deferred income tax liabilities | (114,623 | ) | 11,244 | (103,379 | ) | ||||||
$ | (99,141 | ) | $ | — | $ | (99,141 | ) |
Cash | $ | 1,305 | |
Other current assets | 16,681 | ||
Current assets | 17,986 | ||
Property, plant & equipment | 3,332 | ||
Goodwill | 136,358 | ||
Customer and distributor relationships | 76,420 | ||
Developed technology | 49,600 | ||
Trademarks & tradenames | 4,780 | ||
Other non-current assets | 302 | ||
Total assets acquired | $ | 288,778 | |
Current liabilities assumed | 10,586 | ||
Deferred income taxes | 20,009 | ||
Other long-term liabilities | 454 | ||
Total liabilities assumed | 31,049 | ||
Net assets acquired | $ | 257,729 |
Three Months Ended March 31, | |||||||
2016 | 2015 | ||||||
Net sales | $ | 181,201 | $ | 187,324 | |||
Net income (loss) | 6,323 | (6,856 | ) |
April 1, 2016 - March 31, 2017 | $ | 10,089 | |
April 1, 2017 - March 31, 2018 | 11,296 | ||
April 1, 2018 - March 31, 2019 | 15,792 | ||
April 1, 2019 - March 31, 2020 | 18,336 | ||
April 1, 2020 - March 31, 2021 | 466,920 |
Item 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
• | general economic and business conditions; |
• | changes in foreign exchange and interest rates; |
• | cyclical customer purchasing patterns due to budgetary and other constraints; |
• | changes in customer preferences; |
• | competition; |
• | changes in technology; |
• | the introduction and acceptance of new products; |
• | the ability to evaluate, finance and integrate acquired businesses, products and companies; |
• | changes in business strategy; |
• | the availability and cost of materials; |
• | the possibility that United States or foreign regulatory and/or administrative agencies may initiate enforcement actions against us or our distributors; |
• | future levels of indebtedness and capital spending; |
• | quality of our management and business abilities and the judgment of our personnel; |
• | the availability, terms and deployment of capital; |
• | the risk of litigation, especially patent litigation, as well as the cost associated with patent and other litigation; |
• | the risk of a lack of allograft tissue due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and |
• | compliance with and changes in regulatory requirements. |
Three Months Ended March 31, | |||||
2016 | 2015 | ||||
Orthopedic surgery | 51.6 | % | 55.4 | % | |
General surgery | 41.9 | % | 37.1 | % | |
Surgical visualization | 6.5 | % | 7.5 | % | |
Consolidated net sales | 100.0 | % | 100.0 | % |
• | revenue recognition; |
• | inventory valuation; |
• | goodwill and intangible assets; |
• | pension plan; |
• | stock-based compensation costs; and |
• | income taxes. |
Three Months Ended March 31, | |||||
2016 | 2015 | ||||
Net sales | 100.0 | % | 100.0 | % | |
Cost of sales | 46.1 | 48.1 | |||
Gross profit | 53.9 | 51.9 | |||
Selling and administrative expense | 47.4 | 42.0 | |||
Research and development expense | 4.6 | 3.7 | |||
Income from operations | 1.9 | 6.2 | |||
Other expense | 1.6 | — | |||
Interest expense | 2.1 | 0.8 | |||
Income (loss) before income taxes | (1.8 | ) | 5.4 | ||
Provision (benefit) for income taxes | (0.5 | ) | 1.8 | ||
Net income (loss) | (1.3 | )% | 3.6 | % |
• | Orthopedic surgery sales decreased $5.2 million (-5.2%) to $93.4 million in the three months ended March 31, 2016 from $98.6 million in the three months ended March 31, 2015 due primarily to the impact of unfavorable foreign currency exchange rates. In constant currency, excluding the effects of the hedging program, sales decreased 1.2% as a result of reduced sales of capital equipment outside of the United States. |
• | General surgery sales increased $9.8 million (14.9%) in the three months ended March 31, 2016 to $75.9 million from $66.1 million in the three months ended March 31, 2015. In constant currency, excluding the effects of the hedging program, sales increased 16.7%. Excluding SurgiQuest, sales decreased 4.3% due primarily to the impact of unfavorable foreign currency exchange rates and lower sales of our electrosurgical generators. |
• | Surgical visualization sales decreased $1.3 million (-10.7%) in the three months ended March 31, 2016 to $11.9 million from $13.2 million in the three months ended March 31, 2015 mainly due to lower sales in our 3DHD video systems. In constant currency, excluding the effects of the hedging program, sales decreased 7.7%. |
• | A reduction in accounts receivable reflecting strong collections on fourth quarter 2015 sales; |
• | An increase in inventories during the three months ended March 31, 2016 compared with year-end related to SurgiQuest finished goods and field inventories to support the acquisition integration and anticipated sales growth, and increases associated with anticipated new products launching in 2016. |
• | A decrease in accounts payable due partially to a post-acquisition pay down of acquired SurgiQuest accounts payable to facilitate the consolidation of SurgiQuest systems. |
• | A reduction in accrued compensation and benefits driven primarily by payment of incentive compensation accrued at December 31, 2015. |
• | An increase in other assets due primarily as a result of the reclassification of certain cash balances to restricted cash in conjunction with the SurgiQuest acquisition; restricted cash will be paid out over the balance of the year to former employees of SurgiQuest. |
Payments Due by Period | ||||||||
Total | Less than 1 Year | 1-3 Years | 3-5 Years | |||||
Long-term debt | 522,433 | 10,089 | 27,088 | 485,256 |
Exhibit No. | Description of Exhibit |
31.1 | Certification of Curt R. Hartman pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2 | Certification of Luke A. Pomilio pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1 | Certifications of Curt R. Hartman and Luke A. Pomilio pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
101 | The following materials from CONMED Corporation's Quarterly Report on Form 10-Q for the three months ended March 31, 2016 formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Condensed Statements of Comprehensive Income for the three months ended March 31, 2016 and 2015, (ii) the Consolidated Condensed Balance Sheets at March 31, 2016 and December 31, 2015, (iii) Consolidated Condensed Statements of Cash Flows for the three months ended March 31, 2016 and 2015, and (iv) Notes to Consolidated Condensed Financial Statements for the three months ended March 31, 2016. In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be part of any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. |
CONMED CORPORATION | ||
By: /s/ Luke A. Pomilio | ||
Luke A. Pomilio | ||
Executive Vice President, Finance and | ||
Chief Financial Officer | ||
Date: | ||
May 2, 2016 |
Sequential Page | ||
Exhibit | Number | |
31.1 | Certification of Curt R. Hartman pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | E-1 |
31.2 | Certification of Luke A. Pomilio pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | E-2 |
32.1 | Certifications of Curt R. Hartman and Luke A. Pomilio pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | E-3 |
101 | The following materials from CONMED Corporation’s Quarterly Report on Form 10-Q for the three months ended March 31, 2016 formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Condensed Statements of Comprehensive Income for the three months ended March 31, 2016 and 2015, (ii) the Consolidated Condensed Balance Sheets at March 31, 2016 and December 31, 2015, (iii) Consolidated Condensed Statements of Cash Flows for the three months ended March 31, 2016 and 2015, and (iv) Notes to Consolidated Condensed Financial Statements for the three months ended March 31, 2016. In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be part of any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. |
1. | I have reviewed this quarterly report on Form 10-Q of CONMED Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ Curt R. Hartman | |
Curt R. Hartman | |
President & Chief Executive Officer |
1. | I have reviewed this quarterly report on Form 10-Q of CONMED Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ Luke A. Pomilio | |
Luke A. Pomilio | |
Executive Vice President, Finance and | |
Chief Financial Officer |
Date: | May 2, 2016 | /s/ Curt R. Hartman |
Curt R. Hartman | ||
President & Chief Executive Officer | ||
Date: | May 2, 2016 | /s/ Luke A. Pomilio |
Luke A. Pomilio | ||
Executive Vice President, Finance and | ||
Chief Financial Officer |
Document and Entity Information - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Apr. 28, 2016 |
|
Document and Entity Information [Abstract] | ||
Entity Registrant Name | CONMED CORP | |
Entity Central Index Key | 0000816956 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2016 | |
Document Fiscal Year Focus | 2016 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Common Stock, Shares Outstanding | 27,751,474 |
Consolidated Condensed Statements of Comprehensive Income - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Statement of Comprehensive Income [Abstract] | ||
Net sales | $ 181,201 | $ 177,940 |
Cost of sales | 83,461 | 85,658 |
Gross profit | 97,740 | 92,282 |
Selling and administrative expense | 85,943 | 74,786 |
Research and development expense | 8,258 | 6,542 |
Total operating expenses | 94,201 | 81,328 |
Income from operations | 3,539 | 10,954 |
Other expense | 2,942 | 0 |
Interest expense | 3,830 | 1,460 |
Income (loss) before income taxes | (3,233) | 9,494 |
Provision (benefit) for income taxes | (968) | 3,182 |
Net income (loss) | (2,265) | 6,312 |
Comprehensive income (loss) | $ 787 | $ (3,715) |
Per share data: | ||
Basic (in dollars per share) | $ (0.08) | $ 0.23 |
Diluted (in dollars per share) | (0.08) | 0.23 |
Dividends per share of common stock (in dollars per share) | $ 0.20 | $ 0.20 |
Weighted average common shares: | ||
Basic (shares) | 27,721 | 27,573 |
Diluted (shares) | 27,721 | 27,820 |
Consolidated Condensed Balance Sheets (Parenthetical) - $ / shares |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Preferred stock, par value (dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 500,000 | 500,000 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 31,299,194 | 31,299,194 |
Treasury stock, shares | 3,556,032 | 3,590,409 |
Operations |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Operations | Operations CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. |
Interim Financial Information |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Interim financial information | Interim Financial Information The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. Results for the period ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The consolidated condensed financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended December 31, 2015 included in our Annual Report on Form 10-K. |
Comprehensive Income (Loss) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive Income (Loss) [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive Income | Comprehensive Income (Loss) Comprehensive income (loss) consists of the following:
Accumulated other comprehensive loss consists of the following:
(a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 4 and Note 9, respectively, for further details. |
Fair Value of Financial Instruments |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Financial Instruments | Fair Value of Financial Instruments We enter into derivative instruments for risk management purposes only. We operate internationally and, in the normal course of business, are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument, to manage certain foreign currency exposures. By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance, we do not anticipate any material non-performance by any of these counterparties. Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts. We account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of sales or cost of sales when the forecasted transaction occurs. The notional contract amounts for forward contracts outstanding at March 31, 2016 which have been accounted for as cash flow hedges totaled $101.8 million. Net realized gains recognized for forward contracts accounted for as cash flow hedges approximated $0.5 million and $2.7 million for the three months ended March 31, 2016 and 2015, respectively. Net unrealized losses on forward contracts outstanding, which have been accounted for as cash flow hedges and which have been included in other comprehensive income, totaled $1.0 million at March 31, 2016. It is expected these unrealized losses will be recognized in the consolidated condensed statement of comprehensive income in 2016 and 2017. We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures on intercompany receivables denominated in foreign currencies. These forward contracts settle each month at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them. The notional contract amounts for forward contracts outstanding at March 31, 2016 which have not been designated as hedges totaled $21.3 million. Net realized gains and losses recognized in connection with those forward contracts not accounted for as hedges approximated $(0.3) million and $0.6 million for the three months ended March 31, 2016 and 2015, respectively, offsetting gains and losses on our intercompany receivables of $0.4 million and $(0.7) million for the three months ended March 31, 2016 and 2015, respectively. These gains and losses have been recorded in selling and administrative expense in the consolidated condensed statements of comprehensive income. We record these forward foreign exchange contracts at fair value; the following tables summarize the fair value for forward foreign exchange contracts outstanding at March 31, 2016 and December 31, 2015:
Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated balance sheets. Accordingly, at March 31, 2016 and December 31, 2015, we have recorded the net fair value of $1.6 million in other current liabilities and $1.9 million in prepaid expenses and other current assets, respectively. Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is defined based upon an exit price model. Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets in markets that are not active; inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks or inputs that are derived principally from, or corroborated by, observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2016 consist of forward foreign exchange contracts and contingent liabilities associated with the EndoDynamix, Inc. acquisition. The Company values its forward foreign exchange contracts using quoted prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange contract assets and liabilities were determined within Level 2 of the valuation hierarchy and are listed in the table above. The EndoDynamix, Inc. acquisition involves the potential for the payment of future contingent consideration upon the achievement of certain product development milestones and revenue based payments. Contingent consideration is recorded at the estimated fair value of the contingent milestone and revenue based payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within selling and administrative expenses in the consolidated condensed statements of comprehensive income. We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. The carrying amounts reported in our consolidated condensed balance sheets for cash and cash equivalents, accounts receivable, accounts payable and long-term debt approximate fair value. |
Inventories |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories Inventories consist of the following:
|
Earnings (Loss) Per Share |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share | Earnings Per Share Basic earnings per share (“basic EPS”) is computed by dividing net income by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding resulting from employee stock options, restricted stock units, performance share units and stock appreciation rights ("SARs") during the period. The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2016 and 2015:
The shares used in the calculation of diluted EPS exclude options and SARs to purchase shares where the exercise price was greater than the average market price of common shares for the period and the effect of the inclusion would be anti-dilutive. Such shares were not material in the three months ended March 31, 2015. As the Company was in a net loss position at March 31, 2016, there were no anti-dilutive shares. |
Goodwill and Other Intangible Assets |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets The changes in the net carrying amount of goodwill for the three months ended March 31, 2016 are as follows:
Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. During the three months ended March 31, 2016, the Company acquired SurgiQuest, Inc. ("SurgiQuest") as further described in Note 14. Goodwill resulting from the acquisition amounted to $136.4 million and acquired intangible assets including customer and distributor relationships, developed technology and trademarks and tradenames amounted to $130.8 million. Other intangible assets consist of the following:
Customer and distributor relationships, trademarks and tradenames, developed technology and patents and other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. Promotional, marketing and distribution rights represent intangible assets created under our Sports Medicine Joint Development and Distribution Agreement (the "JDDA") with Musculoskeletal Transplant Foundation (“MTF”). On January 3, 2012, the Company entered into the JDDA with MTF to obtain MTF's worldwide promotion rights with respect to allograft tissues within the field of sports medicine and related products. The initial consideration from the Company included a $63.0 million up-front payment for the rights and certain assets, with an additional $84.0 million contingently payable over a four year period depending on MTF meeting supply targets for tissue. On January 6, 2016, January 5, 2015 and January 3, 2014, we paid equal installments of $16.7 million and on January 3, 2013, we paid $34.0 million of the additional consideration. Amortization expense related to intangible assets which are subject to amortization totaled $5.0 million and $3.2 million in the three months ended March 31, 2016 and 2015, respectively, and is included as a reduction of revenue (for amortization related to our promotional, marketing and distribution rights) and in selling and administrative expense (for all other intangible assets) in the consolidated condensed statements of comprehensive income. The weighted average amortization period for intangible assets which are amortized is 25 years. Customer and distributor relationships are being amortized over a weighted average life of 29 years. SurgiQuest customer and distributor relationships are being amortized over a weighted average life of 22 years. Promotional, marketing and distribution rights are being amortized over a weighted average life of 25 years. Patents and other intangible assets are being amortized over a weighted average life of 13 years. Included in patents and other intangible assets at March 31, 2016 is an in-process research and development asset related to the EndoDynamix, Inc. acquisition that is not currently amortized. Developed technology is being amortized over a weighted average life of 17 years. The estimated intangible asset amortization expense remaining for the year ending December 31, 2016 and for each of the five succeeding years is as follows:
|
Guarantees |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Guarantees [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Guarantees | Guarantees We provide warranties on certain of our products at the time of sale. The standard warranty period for our capital and reusable equipment is generally one year. Liability under service and warranty policies is based upon a review of historical warranty and service claim experience. Adjustments are made to accruals as claim data and historical experience warrant. Changes in the carrying amount of service and product warranties for the three months ended March 31, are as follows:
|
Pension Plan |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension Plan | Pension Plan Net periodic pension cost consists of the following:
We do not expect to make any pension contributions during 2016. |
Acquisition, Restructuring and Other Expense |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition, Restructuring and Other Expense [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition, Restructuring and Other Expense [Text Block] | Acquisition, Restructuring and Other Expense Acquisition, restructuring and other expense consists of the following:
During the three months ended March 31, 2016, we incurred $9.0 million in costs associated with the January 4, 2016 acquisition of SurgiQuest, Inc. as further described in Note 14. These costs include investment banking fees, consulting fees, legal fees and integration related costs. During the three months ended March 31, 2016, we incurred a $2.7 million charge related to an agreement between the Company and JP Morgan Chase Bank, N.A. and recorded a loss on the early extinguishment of debt of $0.3 million in conjunction with the fifth amended and restated senior credit agreement as further described in Note 15. During 2016 and 2015, we continued our operational restructuring plan. The consolidation of our Centennial, Colorado manufacturing operations into other existing CONMED manufacturing facilities is substantially complete. We incurred $0.9 million and $2.3 million in costs associated with the operational restructuring during the three months ended March 31, 2016 and 2015, respectively. These costs were charged to cost of sales and include severance and other charges associated with the consolidation. In conjunction with the consolidation of our Centennial, Colorado manufacturing operations, the facility is currently held for sale and classified in prepaids and other current assets in the consolidated condensed balance sheet. The net book value of this facility at March 31, 2016 was $3.1 million. During 2016 and 2015, we restructured certain selling and administrative functions and incurred severance and other related costs in the amount of $2.8 million and $6.2 million for the three months ended March 31, 2016 and 2015, respectively. We have recorded an accrual in current and other long term liabilities of $3.9 million at March 31, 2016 mainly related to severance costs associated with the restructuring. Below is a rollforward of the costs incurred and cash expenditures associated with these activities during the three months ended March 31, 2016 and 2015:
|
Business Segments |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segments | Business Segments We are accounting and reporting for our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Our chief operating decision maker (the CEO) evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources. Our product lines consist of orthopedic surgery, general surgery and surgical visualization. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. Surgical visualization consists of imaging systems for use in minimally invasive orthopedic and general surgery procedures including 2DHD and 3DHD vision technologies. These product lines' net sales are as follows:
|
Legal Proceedings |
3 Months Ended |
---|---|
Mar. 31, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | |
Legal Proceedings | Legal Proceedings From time to time, we are subject to claims alleging product liability, patent infringement or other claims incurred in the ordinary course of business. These may involve our United States or foreign operations, or sales by foreign distributors. Likewise, from time to time, the Company may receive an information request or subpoena from a government agency such as the Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the Department of Labor, the Treasury Department or other federal and state agencies or foreign governments or government agencies. These information requests or subpoenas may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions of various types. The product liability claims are generally covered by various insurance policies, subject to certain deductible amounts, maximum policy limits and certain exclusions in the respective policies or as required as a matter of law. In some cases, we may be entitled to indemnification by third parties. We establish reserves sufficient to cover probable losses associated with any such pending claims. We do not expect that the resolution of any pending claims or investigations will have a material adverse effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims or investigations, or the costs associated with responding to such claims or investigations, especially claims and investigations not covered by insurance, will not have a material adverse effect on our financial condition, results of operations or cash flows. Manufacturers of medical products may face exposure to significant product liability claims. To date, we have not experienced any product liability claims that have been material to our financial statements or financial condition, but any such claims arising in the future could have a material adverse effect on our business or results of operations. We currently maintain commercial product liability insurance of $25 million per incident and $25 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis. There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance will be available to us in the future at a reasonable cost. Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing, among other things, air emissions; wastewater discharges; the use, handling and disposal of hazardous substances and wastes; soil and groundwater remediation and employee health and safety. In some jurisdictions, environmental requirements may be expected to become more stringent in the future. In the United States, certain environmental laws can impose liability for the entire cost of site restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the party’s activities. While we do not believe that the present costs of environmental compliance and remediation are material, there can be no assurance that future compliance or remedial obligations would not have a material adverse effect on our financial condition, results of operations or cash flows. During the third quarter of 2013, the U.S. Food and Drug Administration ("FDA") inspected our Centennial, Colorado manufacturing facility and issued a Form 483 with observations on September 20, 2013. We subsequently submitted responses to the Observations, and the FDA issued a warning letter on January 30, 2014 relating to the inspection and the responses to the Form 483 observations. Accordingly, we undertook corrective actions. During the fourth quarter of 2014, the FDA again inspected our Centennial, Colorado manufacturing facility and, on November 18, 2014, issued a Form 483 with eight observations, three of which the FDA characterized as repeat observations. On December 10, 2014, we responded to the Form 483 observations. We have received some additional questions from the FDA and have responded to these questions on April 25, 2015. The remediation costs to date have not been material, although there can be no assurance that responding to the Form 483 observations or a future inspection by the FDA will not result in an additional Form 483 or warning letter, or other regulatory actions, which may include consent decrees or fines that could be material. |
New Accounting Pronouncements |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New Accounting Pronouncements and Changes in Accounting Principles [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New Accounting Pronouncements | New Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers". This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration the company expects to receive in exchange for those goods or services. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 by one year. This ASU is effective for annual reporting periods beginning after December 15, 2017 and early adoption is permitted as of January 1, 2017. We plan to adopt this ASU on January 1, 2018. The new standard will become effective beginning with the first quarter of 2018 and can be adopted either retrospectively to each prior reporting period presented or as a cumulative effect adjustment as of the date of adoption. The Company is currently evaluating both the impact of adopting this new guidance on the consolidated financial statements and the method of adoption. In July 2015, the FASB issued ASU No. 2015-11, "Simplifying the Measurement of Inventory". An entity should measure inventory within the scope of this Update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. This ASU is effective for annual periods beginning after December 15, 2016. The Company does not believe this new guidance will have a material impact on the consolidated financial statements. In August 2015, the FASB issued ASU No. 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements". This ASU was issued to clarify the guidance included in ASU 2015-03 "Simplifying the Presentation of Debt Issuance Costs", which requires entities to present debt issuance costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability. ASU 2015-03 does not address presentation or subsequent measurement of debt issuance costs related to line-of-credit arrangements. Given the absence of authoritative guidance within Update 2015-03 for debt issuance costs related to line-of-credit arrangements, ASU 2015-15 was issued to clarify that the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. This ASU is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted this guidance as of January 1, 2016 and it did not have a material impact on our consolidated financial statements. In September 2015, the FASB issued ASU No. 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments". This ASU simplifies the accounting for changes in measurement period adjustments associated with a business combination. It requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This ASU is effective for annual periods beginning after December 15, 2015. The Company adopted this guidance as of January 1, 2016 and it did not have a material impact on our consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17 "Income Taxes (ASC 740): Balance Sheet Classification of Deferred Taxes". This ASU requires all deferred income tax assets and liabilities be presented as non-current in classified balance sheets. This can be applied prospectively or retrospectively and must disclose the reason for the change in accounting principle, the application applied and if applied retrospectively, include quantitative information about the effects of the change on prior periods. This standard is effective for annual and interim periods beginning after December 15, 2016. The Company retrospectively implemented this new guidance in the first quarter of 2016. The below table summarizes the adjustments made to conform prior period classification with the new guidance:
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). This requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. ASU 2016-02 states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The new standard is effective for interim and annual periods beginning after December 15, 2018 and early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-02. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU requires all tax effects to run through the statement of operations, where historically tax benefits in excess of compensation cost ran through equity. It also allows employers' to withhold the maximum amount of individual tax withholdings without resulting in liability accounting. Finally, the ASU allows companies to make an accounting policy election regarding the impact of forfeitures on expense related to share based awards. This new guidance is effective for periods beginning after December 15, 2016, however early adoption is permitted. The Company is currently evaluating the impact of adopting this new guidance on the consolidated financial statements. |
Business Acquisition |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Acquisition | Business Acquisition On January 4, 2016, we acquired all of the stock of SurgiQuest, Inc. ("SurgiQuest") for $257.7 million in cash (based on an aggregate purchase price of $265 million as adjusted pursuant to the merger agreement governing the acquisition). SurgiQuest develops, manufactures and markets the AirSeal® System, the first integrated access management technology for use in laparoscopic and robotic procedures. This proprietary and differentiated access system is complementary to our current advanced surgical offering. The acquisition was funded through a combination of cash on hand and long-term borrowings. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the SurgiQuest acquisition. The assessment of fair value is preliminary and is based on information that was available to management at the time the consolidated condensed financial statements were prepared. Accordingly, the allocation of purchase price is preliminary and therefore subject to adjustment in future periods.
The goodwill recorded as part of the acquisition primarily represents revenue synergies, as well as operating efficiencies and cost savings. Goodwill deductible for tax purposes is $11.5 million. The weighted amortization period for intangibles acquired is 20 years. Customer and distributor relationships, developed technology and trademarks and tradenames are being amortized over a weighted average life of 22, 17 and 23 years, respectively. The unaudited pro forma information for the quarters ended March 31, 2016 and 2015, assuming SurgiQuest occurred as of January 1, 2015 are presented below. This information has been prepared for comparative purposes only and does not purport to be indicative of the results of operations which actually would have resulted had the SurgiQuest acquisition occurred on the dates indicated, or which may result in the future.
These pro forma results include certain adjustments, primarily due to increases in amortization expense due to fair value adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition, and acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services as well as integration costs such as severance and retention. Acquisition related costs included in the determination of pro forma net income for the three months ended March 31, 2015 totaled $9.0 million and are included in selling and administrative expenses on the consolidated condensed statement of comprehensive income (loss). Such amounts are excluded from the determination of pro forma net income for the three months ended March 31, 2016. Net sales associated with SurgiQuest of $12.7 million have been recorded in the consolidated condensed statement of comprehensive income (loss) for the three months ended March 31, 2016. It is impracticable to determine the earnings recorded in the consolidated condensed statement of comprehensive income (loss) for the three months ended March 31, 2016 as these amounts are not separately measured. |
Amended and Restated Senior Credit Agreement |
3 Months Ended | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||
Amended and Restated Senior Credit Agreement | Amended and Restated Senior Credit Agreement On January 4, 2016 we entered into an amended and restated senior credit agreement (the "fifth amended and restated senior credit agreement") consisting of: (a) a $175.0 million term loan facility and (b) a $525.0 million revolving credit facility both expiring on January 4, 2021. The term loan is payable in quarterly installments increasing over the term of the facility. Proceeds from the term loan facility and borrowings under the revolving credit facility were used to repay the then existing senior credit agreement and to finance the acquisition of SurgiQuest. Initially, the interest rates are at LIBOR plus a base rate or a Eurocurrency rate plus an applicable margin. The applicable margin for base rate loans is 1.00% and for Eurocurrency rate loans is 2.00% (2.43% at March 31, 2016). In conjunction with this agreement, we incurred charges included in other expense in the statements of comprehensive income (loss) related to an agreement between the Company and JP Morgan Chase Bank, N.A. totaling $2.7 million and recorded a loss on the early extinguishment of debt of $0.3 million. There were $172.8 million in borrowings outstanding on the term loan as of March 31, 2016. There were $344.4 million in borrowings outstanding under the revolving credit facility as of March 31, 2016. Our available borrowings on the revolving credit facility at March 31, 2016 were $175.5 million with approximately $5.1 million of the facility set aside for outstanding letters of credit. The amended and restated senior credit agreement is collateralized by substantially all of our personal property and assets. The amended and restated senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of March 31, 2016. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issuance of equity and asset sales. The scheduled maturities of long-term debt outstanding at March 31, 2016 are as follows:
|
Comprehensive Income (Loss) (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive Income (Loss) [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Comprehensive Income | Comprehensive income (loss) consists of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accumulated Other Comprehensive Loss | Accumulated other comprehensive loss consists of the following:
(a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 4 and Note 9, respectively, for further details. |
Fair Value of Financial Instruments (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value for Forward Foreign Exchange Contracts | We record these forward foreign exchange contracts at fair value; the following tables summarize the fair value for forward foreign exchange contracts outstanding at March 31, 2016 and December 31, 2015:
|
Inventories (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of inventory | Inventories consist of the following:
|
Earnings (Loss) Per Share (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of calculation of basic and diluted earnings per share | The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2016 and 2015:
|
Goodwill and Other Intangible Assets (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Goodwill | The changes in the net carrying amount of goodwill for the three months ended March 31, 2016 are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets | Other intangible assets consist of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Estimated Amortization Expense | The estimated intangible asset amortization expense remaining for the year ending December 31, 2016 and for each of the five succeeding years is as follows:
|
Guarantees (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Guarantees [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in the carrying amount of service and product warranties | Changes in the carrying amount of service and product warranties for the three months ended March 31, are as follows:
|
Pension Plan (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of net benefit cost | Net periodic pension cost consists of the following:
|
Acquisition, Restructuring and Other Expense (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition, Restructuring and Other Expense [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Acquisition, Restructuring and Other Expense [Table Text Block] | Acquisition, restructuring and other expense consists of the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Accrual | Below is a rollforward of the costs incurred and cash expenditures associated with these activities during the three months ended March 31, 2016 and 2015:
|
Business Segments (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of net sales information by product line | These product lines' net sales are as follows:
|
New Accounting Pronouncements New Accounting Pronouncements (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New Accounting Pronouncements and Changes in Accounting Principles [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of New Accounting Pronouncements and Changes in Accounting Principles | The below table summarizes the adjustments made to conform prior period classification with the new guidance:
|
Business Acquisition Business Acquisition (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the SurgiQuest acquisition. The assessment of fair value is preliminary and is based on information that was available to management at the time the consolidated condensed financial statements were prepared. Accordingly, the allocation of purchase price is preliminary and therefore subject to adjustment in future periods.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Acquisition, Pro Forma Information [Table Text Block] |
|
Amended and Restated Senior Credit Agreement Amended and Restated Senior Credit Agreement (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||
Schedule of Maturities of Long-term Debt [Table Text Block] |
|
Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Comprehensive Income (Loss) [Abstract] | ||
Net income (loss) | $ (2,265) | $ 6,312 |
Pension liability, net of income tax | 438 | 512 |
Pension liability, tax | 257 | 300 |
Cash flow hedging gain (loss), net of income tax | (2,217) | 1,962 |
Cash flow hedging gain (loss), tax | (1,299) | 1,150 |
Foreign currency translation adjustment | 4,831 | (12,501) |
Comprehensive income (loss) | $ 787 | $ (3,715) |
Fair Value of Financial Instruments (Foreign Currency Forward Contracts) (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
Dec. 31, 2015 |
|
Derivative [Line Items] | |||
Gains (losses) on intercompany receivables | $ 400 | $ (700) | |
Derivative Assets and Liabilities at Fair Value [Abstract] | |||
Fair value, assets | 937 | $ 2,935 | |
Fair value, liabilities | (2,567) | (1,064) | |
Derivative Assets (Liabilities), at Fair Value, Net | (1,630) | 1,871 | |
Foreign Currency Forward Contracts [Member] | |||
Derivative [Line Items] | |||
Forward contracts not designated as hedging instruments net realized gains (losses) | (300) | 600 | |
Designated as Hedging Instrument [Member] | Foreign Currency Forward Contracts [Member] | Prepaid Expenses and Other Current Assets [Member] | |||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||
Fair value, assets | 2,931 | ||
Fair value, liabilities | (1,026) | ||
Derivative Assets (Liabilities), at Fair Value, Net | 1,905 | ||
Designated as Hedging Instrument [Member] | Foreign Currency Forward Contracts [Member] | Other Current Liabilities [Member] | |||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||
Fair value, assets | 930 | ||
Fair value, liabilities | (2,541) | ||
Derivative Assets (Liabilities), at Fair Value, Net | (1,611) | ||
Not Designated as Hedging Instrument [Member] | Foreign Currency Forward Contracts [Member] | |||
Derivative [Line Items] | |||
Notional amount of cash flow hedges | 21,300 | ||
Not Designated as Hedging Instrument [Member] | Foreign Currency Forward Contracts [Member] | Prepaid Expenses and Other Current Assets [Member] | |||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||
Fair value, assets | 4 | ||
Fair value, liabilities | (38) | ||
Derivative Assets (Liabilities), at Fair Value, Net | $ (34) | ||
Not Designated as Hedging Instrument [Member] | Foreign Currency Forward Contracts [Member] | Other Current Liabilities [Member] | |||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||
Fair value, assets | 7 | ||
Fair value, liabilities | (26) | ||
Derivative Assets (Liabilities), at Fair Value, Net | (19) | ||
Cash Flow Hedging [Member] | Foreign Currency Forward Contracts [Member] | |||
Derivative [Line Items] | |||
Notional amount of cash flow hedges | 101,800 | ||
Cash flow hedges realized gains | 500 | $ 2,700 | |
Unrealized gains on cash flow hedges in accumulated other comprehensive income (loss) expected to be recognized in the next fiscal year | $ (1,000) |
Inventories (Details) - USD ($) $ in Thousands |
Mar. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw materials | $ 50,533 | $ 47,681 |
Work-in-process | 15,211 | 13,922 |
Finished goods | 119,364 | 105,291 |
Total inventory | $ 185,108 | $ 166,894 |
Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Earnings Per Share [Abstract] | ||
Net income (loss) | $ (2,265) | $ 6,312 |
Basic-weighted average shares outstanding | 27,721 | 27,573 |
Effect of dilutive potential securities | 0 | 247 |
Diluted- weighted average shares outstanding | 27,721 | 27,820 |
Basic (in dollars per share) | $ (0.08) | $ 0.23 |
Diluted (in dollars per share) | $ (0.08) | $ 0.23 |
Goodwill and Other Intangible Assets (Goodwill) (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2016
USD ($)
| |
Goodwill [Roll Forward] | |
Beginning balance | $ 260,651 |
Goodwill resulting from business acquisitions | 136,358 |
Foreign currency translation | 1,378 |
Ending balance | $ 398,387 |
Goodwill and Other Intangible Assets (Intangible Assets) (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Dec. 31, 2015 |
|
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | ||
Intangible assets, Gross carrying amount | $ 570,500 | $ 439,479 |
Intangible assets, Accumulated amortization | (136,304) | (131,308) |
Future amortization expense [Abstract] | ||
Remaining, 2016 | 15,199 | |
2017 | 21,422 | |
2018 | 21,740 | |
2019 | 21,600 | |
2020 | 21,265 | |
2021 | 20,010 | |
Expense [Member] | ||
Future amortization expense [Abstract] | ||
Remaining, 2016 | 10,699 | |
2017 | 15,422 | |
2018 | 15,740 | |
2019 | 15,600 | |
2020 | 15,265 | |
2021 | 14,010 | |
Reduction of Revenue [Member] | ||
Future amortization expense [Abstract] | ||
Remaining, 2016 | 4,500 | |
2017 | 6,000 | |
2018 | 6,000 | |
2019 | 6,000 | |
2020 | 6,000 | |
2021 | 6,000 | |
Trademarks and Tradenames [Member] | ||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | ||
Unamortized intangible assets, Gross carrying amount | 86,544 | 86,544 |
Customer and Distributor Relationships [Member] | ||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | ||
Amortized intangible assets, Gross carrying amount | 213,338 | 136,871 |
Intangible assets, Accumulated amortization | (67,110) | (64,423) |
Promotional, Marketing and Distribution Rights [Member] | ||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | ||
Amortized intangible assets, Gross carrying amount | 149,376 | 149,376 |
Intangible assets, Accumulated amortization | (25,500) | (24,000) |
Patents and Other Intangible Assets [Member] | ||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | ||
Amortized intangible assets, Gross carrying amount | 71,642 | 66,688 |
Intangible assets, Accumulated amortization | (43,384) | (42,885) |
Technology-Based Intangible Assets [Member] | ||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | ||
Amortized intangible assets, Gross carrying amount | 49,600 | 0 |
Intangible assets, Accumulated amortization | (310) | $ 0 |
SurgiQuestInc [Member] | ||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | ||
Finite-lived Intangible Assets Acquired | $ 130,800 |
Goodwill and Other Intangible Assets (Other Intangible Assets) (Details) - USD ($) $ in Millions |
3 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|
Jan. 06, 2016 |
Jan. 04, 2016 |
Jan. 05, 2015 |
Jan. 03, 2014 |
Jan. 03, 2013 |
Jan. 03, 2012 |
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Other Intangible Assets [Line Items] | ||||||||
Up-front payment | $ 63.0 | |||||||
Additional contingent cash payment | $ 84.0 | |||||||
Contingent payment period (in years) | 4 years | |||||||
Amortization expense | $ 5.0 | $ 3.2 | ||||||
Weighted average amortization period (in years) | 25 years | |||||||
Promotional, Marketing and Distribution Rights [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Weighted average amortization period (in years) | 25 years | |||||||
Customer and Distributor Relationships [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Weighted average amortization period (in years) | 29 years | |||||||
Patents and Other Intangible Assets [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Weighted average amortization period (in years) | 13 years | |||||||
Technology-Based Intangible Assets [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Weighted average amortization period (in years) | 17 years | |||||||
After One Year of Meeting Supply Target [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Conditional payment, amount paid | $ 34.0 | |||||||
After Two Year of Meeting Supply Target [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Conditional payment, amount paid | $ 16.7 | |||||||
After Year Three of Meeting Supply Target [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Conditional payment, amount paid | $ 16.7 | |||||||
After Year Four of Meeting Supply Target [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Conditional payment, amount paid | $ 16.7 | |||||||
SurgiQuestInc [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Weighted average amortization period (in years) | 20 years | |||||||
SurgiQuestInc [Member] | Customer and Distributor Relationships [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Weighted average amortization period (in years) | 22 years | |||||||
SurgiQuestInc [Member] | Technology-Based Intangible Assets [Member] | ||||||||
Other Intangible Assets [Line Items] | ||||||||
Weighted average amortization period (in years) | 17 years |
Guarantees (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Guarantees [Abstract] | ||
Standard warranty period (in years) | 1 year | |
Movement in Standard Product Warranty Accrual [Roll Forward] | ||
Beginning balance | $ 2,509 | $ 2,286 |
Provision for warranties | 833 | 951 |
Claims made | (841) | (873) |
Ending balance | $ 2,501 | $ 2,364 |
Pension Plan (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Compensation and Retirement Disclosure [Abstract] | ||
Service cost | $ 113 | $ 67 |
Interest cost on projected benefit obligation | 719 | 888 |
Expected return on plan assets | (1,297) | (1,469) |
Net amortization and deferral | 695 | 812 |
Net periodic pension cost | $ 230 | $ 298 |
Acquisition, Restructuring and Other Expense (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Acquisition, Restructuring and Other Expense [Line Items] | ||||
Restructuring costs | $ 3,655 | $ 8,509 | ||
Debt refinancing costs included in other expense | 2,942 | 0 | ||
Debt Instrument, Financing Costs Expensed | 2,700 | |||
Loss on early extinguishment of debt | 254 | 0 | ||
Assets held-for-sale | 3,100 | |||
Restructuring reserve | 3,875 | 8,878 | $ 7,175 | $ 8,254 |
Cost of Sales [Member] | Facility Consolidation Costs [Member] | ||||
Acquisition, Restructuring and Other Expense [Line Items] | ||||
Restructuring costs | 864 | 2,329 | ||
Selling and Administrative Expenses [Member] | ||||
Acquisition, Restructuring and Other Expense [Line Items] | ||||
Acquisition, restructuring and other expense included in selling and administrative expense | 11,836 | 6,180 | ||
Selling and Administrative Expenses [Member] | Administrative Restructuring [Member] | ||||
Acquisition, Restructuring and Other Expense [Line Items] | ||||
Restructuring costs | 2,791 | 6,180 | ||
Other Expense [Member] | ||||
Acquisition, Restructuring and Other Expense [Line Items] | ||||
Debt refinancing costs included in other expense | 2,942 | 0 | ||
SurgiQuestInc [Member] | Selling and Administrative Expenses [Member] | ||||
Acquisition, Restructuring and Other Expense [Line Items] | ||||
Business acquisition costs | $ 9,045 | $ 0 |
Acquisition, Restructuring and Other Expense (Restructuring Accrual) (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Restructuring accrual | ||
Restructuring accrual, beginning balance | $ 7,175 | $ 8,254 |
Expenses incurred | 3,655 | 8,509 |
Payments made | (6,955) | (7,885) |
Restructuring accrual, ending balance | $ 3,875 | $ 8,878 |
Business Segments (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Segment Reporting Information [Line Items] | ||
Net sales | $ 181,201 | $ 177,940 |
Orthopedic Surgery [Member] | ||
Segment Reporting Information [Line Items] | ||
Net sales | 93,441 | 98,597 |
General Surgery [Member] | ||
Segment Reporting Information [Line Items] | ||
Net sales | 75,902 | 66,062 |
Surgical Visualization [Member] | ||
Segment Reporting Information [Line Items] | ||
Net sales | $ 11,858 | $ 13,281 |
Legal Proceedings (Details) $ in Millions |
Mar. 31, 2016
USD ($)
|
---|---|
Commitments and Contingencies Disclosure [Abstract] | |
Product liability insurance, amount per incident | $ 25 |
Product liability insurance, aggregate annual amount | $ 25 |
New Accounting Pronouncements New Accounting Pronouncements (Details) $ in Thousands |
Dec. 31, 2015
USD ($)
|
---|---|
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Current deferred income tax assets | $ 0 |
Long-term deferred income tax assets | 4,238 |
Long-term deferred income tax liabilities | (103,379) |
Deferred Tax Liabilities, Net | (99,141) |
Previous Accounting Guidance [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Current deferred income tax assets | 14,150 |
Long-term deferred income tax assets | 1,332 |
Long-term deferred income tax liabilities | (114,623) |
Deferred Tax Liabilities, Net | (99,141) |
Adjustments for New Accounting Pronouncement [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Current deferred income tax assets | (14,150) |
Long-term deferred income tax assets | 2,906 |
Long-term deferred income tax liabilities | 11,244 |
Deferred Tax Liabilities, Net | $ 0 |
Business Acquisition Business Acquisition (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Jan. 04, 2016 |
Mar. 31, 2016 |
Mar. 31, 2015 |
Dec. 31, 2015 |
|
Business Acquisition [Line Items] | ||||
Weighted average amortization period (in years) | 25 years | |||
Net sales | $ 181,201 | $ 177,940 | ||
Assets Acquired [Abstract] | ||||
Goodwill | $ 398,387 | $ 260,651 | ||
Customer and Distributor Relationships [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average amortization period (in years) | 29 years | |||
Technology-Based Intangible Assets [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average amortization period (in years) | 17 years | |||
SurgiQuestInc [Member] | ||||
Business Acquisition [Line Items] | ||||
Business Combination, Consideration Transferred | $ 257,729 | |||
Payments to acquire business | 265,000 | |||
Tax deductible goodwill | $ 11,500 | |||
Weighted average amortization period (in years) | 20 years | |||
Net sales | $ 12,700 | |||
Assets Acquired [Abstract] | ||||
Cash | $ 1,305 | |||
Other current assets | 16,681 | |||
Current assets | 17,986 | |||
Property, plant & equipment | 3,332 | |||
Goodwill | 136,358 | |||
Other non-current assets | 302 | |||
Total assets acquired | 288,778 | |||
Liabilities Assumed [Abstract] | ||||
Current liabilities assumed | 10,586 | |||
Deferred income taxes | 20,009 | |||
Other long-term liabilities | 454 | |||
Total liabilities assumed | 31,049 | |||
Net assets acquired | $ 257,729 | |||
Pro Forma Information [Abstract] | ||||
Net sales | 181,201 | 187,324 | ||
Net income (loss) | 6,323 | (6,856) | ||
SurgiQuestInc [Member] | Selling and Administrative Expenses [Member] | ||||
Business Acquisition [Line Items] | ||||
Business acquisition costs | $ 9,045 | $ 0 | ||
SurgiQuestInc [Member] | Customer and Distributor Relationships [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average amortization period (in years) | 22 years | |||
Assets Acquired [Abstract] | ||||
Finite-lived intangible assets | $ 76,420 | |||
SurgiQuestInc [Member] | Technology-Based Intangible Assets [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average amortization period (in years) | 17 years | |||
Assets Acquired [Abstract] | ||||
Finite-lived intangible assets | $ 49,600 | |||
SurgiQuestInc [Member] | Trademarks and Tradenames [Member] | ||||
Business Acquisition [Line Items] | ||||
Weighted average amortization period (in years) | 23 years | |||
Assets Acquired [Abstract] | ||||
Finite-lived intangible assets | $ 4,780 |
Amended and Restated Senior Credit Agreement (Details) - USD ($) |
3 Months Ended | ||
---|---|---|---|
Jan. 04, 2016 |
Mar. 31, 2016 |
Mar. 31, 2015 |
|
Debt Instrument [Line Items] | |||
Effective interest rate (percentage) | 2.43% | ||
Debt Instrument, Financing Costs Expensed | $ 2,700,000 | ||
Loss on early extinguishment of debt | 254,000 | $ 0 | |
Remaining borrowing capacity | 175,500,000 | ||
Letters of Credit Outstanding, Amount | 5,100,000 | ||
Maturities of Long-term Debt [Abstract] | |||
April 1, 2016 - March 31, 2017 | 10,089,000 | ||
April 1, 2017 - March 31, 2018 | 11,296,000 | ||
April 1, 2018 - March 31, 2019 | 15,792,000 | ||
April 1, 2019 - March 31, 2020 | 18,336,000 | ||
April 1, 2020 - March 31, 2021 | 466,920,000 | ||
Amended and Restated Senior Credit Agreement [Member] | Base Rate [Member] | |||
Debt Instrument [Line Items] | |||
Variable rate (percentage) | 1.00% | ||
Amended and Restated Senior Credit Agreement [Member] | Eurodollar [Member] | |||
Debt Instrument [Line Items] | |||
Variable rate (percentage) | 2.00% | ||
Loans Payable [Member] | |||
Debt Instrument [Line Items] | |||
Long-term Debt | 172,800,000 | ||
Loans Payable [Member] | Amended and Restated Senior Credit Agreement [Member] | |||
Debt Instrument [Line Items] | |||
Face amount | $ 175,000,000 | ||
Line of Credit [Member] | |||
Debt Instrument [Line Items] | |||
Long-term Debt | $ 344,400,000 | ||
Line of Credit [Member] | Amended and Restated Senior Credit Agreement [Member] | |||
Debt Instrument [Line Items] | |||
Borrowing capacity | $ 525,000,000 |
)^;=YE=7X*8?=
MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^
M 1C/XW
ME&[ZWY^8ZR;GL,1,N9I=NP04=N?VBP=3D_L ']_57E@D*H $$X@C$?QITH:QRE68()!!(_"I((I!$(/FK0YL@
MT 2!)L>@QZT.^PBA.E-49WI S<@W0"D]C((G(2%9&6I[#80.]N/G(B%9&6Q[#<0
M>]L?.1$+2>Q&J/-AE:%^/B,DSBD?-6;.40!79APZM^[$6>S,+TLK'CD+S6Z%
MXMR_$\7>GG#O+-E"@X(5BG,33Q1[%R/HJMEYU(PU2],81NG7#0^LTZ\E[*9O
M!>X5]-[I2\CJG6^>5Z1/SZ<\SWI\([\PN]4=]RY4R#-8'YA72@61J00OLKR5
MO!OG1D.N0GVFJN[FMC -0?OI\IMOX/P_4$L#!!0 ( /6%HD@4-D.] &PO=V]R:W-H965T $1$**2V6
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MEL3,8LFU'X/8@P2@[\C,6P*+A!IQ$1(2#P8\B HBR6UKW 51
MD#X$D'0V+:^($'T*0S9CD')NG,V,ZCB@C8WHVK2A
M\$ ZILQ(='\4T94O:&(6?ZXHPN3&'F@X$ED1@%&OP6714+=N@B*L0<&\/<$
MM4BH$1=!,?$ "9>\YCXSJ,+D"A=:WT^WT *2 '//W?SV<.S3J)EGX2?(3F:
M>4#M\QF-"V6"N1;:O!J?1,__G4+M=*Q4S7$\9FR#7?U>=4,?6NO]*/,5AM.U
MI_8M7V7 !RN2<6# W:]6Q(/Y:!_;'%*(.[ I%#HX:4F4?F\>TSA8,8YXG[;Y9G\0GW=
MQ4#\3*&SB(J<-_J1DHVS=H[#NJWPRA1.]A=N;)G(%B]D47"2NS2&V99THCLZ
MT,+H0+;3PG+7?0S+<:M4"G17H.FQ=,>&\R7)LH>DO- +[(*X<#*/BD>9B>5]44'R^QMABYOW T&],4X
M85K_'5Z:N.M+S+$4_":?5R2(%C#&3];5)G 7S6GKCZF;@<;'-?,C?I)ZE$!M$ ]XE_N&'C5]M.O;I4[L!S
PXO$JD+8T3^.P$5
MXS&(@EO@M6\[;0.X+/!<5_<,N.H%1Q*:8_ 4'4ZYS7 )OWL8U:*/K/>S$&]V
M\+,^!J&U !0J;16(::[P#)1:(0/^.VE^(&WALG]3_^Y6:]R?B8)G0?_TM>Z,
MV3! -33D0O6K&'_ M(34"E:"*O=%U45IP6XE 6+DW;<]=^WH9_)D*MLNB*>"
M>"Z(O7$/+/\7)FJ0;,,.NJ"PAI;O HQ;.;"R#VYDM/F.,I9J%%4
M9!:!B>%PG2E""5AL/)A*/R5Y1B